期刊文献+

Crizotinib对NSCLC裸鼠HGF表达影响及生存分析

The effect of crizotinib on the expression of hepatocyte growth factor in non-small cell lung cancer and its survival analysis
原文传递
导出
摘要 目的:研究Crizotinib对非小细胞肺癌裸鼠肝细胞生长因子表达及生存情况影响。方法:我们将60只裸鼠分组造模后,用不同药物灌胃给药。比较药物治疗后三组大鼠的肿瘤生长情况,分析比较三组大鼠8周生存率,采用ELISA法测定治疗前后大鼠血清HGF水平。结果:Crizotinib灌胃组裸鼠肿瘤增长速度明显降低,血清HGF水平迅速增长,生存时间延长。结论:Crizotinib可有效抑制非小细胞肺癌生长,降低血清肝细胞生长因子表达水平,提高裸鼠8周生存率,Crizotinib可有效治疗裸鼠非小细胞肺癌。 Objective To investigate the effect of Crizotinib on hepatocyte growth factor expression and survival in non-small cell lung cancer in nude mice.Methods We divided 60 nude mice into groups and then administered gavage with different drugs.The tumor growth of the three groups of rats after drug treatment was compared.The 8-week survival rate of the three groups of rats was compared.The serum HGF levels of the rats before and after treatment were determined by ELISA.Results It was found that the tumor growth rate of Crizotinib group was significantly decreased,serum HGF level increased rapidly and survival time was prolonged.Crizotinib can effectively inhibit the growth of non-small cell lung cancer,reduce the expression of serum hepatocyte growth factor,improve the survival rate of 8-week nude mice.Conclusion Crizotinib can effectively treat non-small cell lung cancer in nude mice.
作者 金岩 杨镇嘉 Jin Yan;Yang Zhen-jia(Chifeng University Affiliated Hospital Respiratory and Critical Care Medicine,Chifeng 024001,China)
出处 《湖南师范大学学报(医学版)》 2021年第4期117-120,共4页 Journal of Hunan Normal University(Medical Sciences)
关键词 克里唑蒂尼 裸鼠 非小细胞肺癌 肝细胞生长因子 生存分析 crizotinib rat non-small cell lung cancer hepatocyte growth factor survival analysis
  • 相关文献

参考文献4

二级参考文献50

  • 1徐平,皮佳俐,刘媛媛,宋卫东.IGF-1和IGFBP-3在肺癌患者血清中的表达及临床意义[J].湖南师范大学学报(医学版),2007,4(1):11-14. 被引量:3
  • 2Jemal A,Siegel R,Ward E. Cancer statistics[J].CA:A Cancer Journal for Clinicians,2007,(01):43-66.
  • 3Govindan R,Page N,Morgensztern D. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:Analysis of the surveillance,epidemiologic,and end results database[J].Journal of Clinical Oncology,2006,(28):4539-4544.
  • 4Yang P,Allen MS,Aubry MC. Clinical features of 5 628 primary lung cancer patients:Experience at mayo clinic from 1997 to 2003[J].Chest,2005,(01):452-462.
  • 5Maemondo M,Inoue A,Kobayashi K. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR[J].New England Journal of Medicine,2010,(25):2380-2388.
  • 6Ciardiello F,Jezdic S. New insights on personalized cancer treatment:A report from the ESMO congress[J].Expert Review of Anticancer Therapy,2011,(01):21-23.
  • 7Soda M,Choi YL,Enomoto M. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer[J].Nature,2007,(7153):561-566.
  • 8Kwak EL,Bang YJ,Camidge DR. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer[J].New England Journal of Medicine,2010,(18):1693-1703.
  • 9Rodig SJ,Shapiro GI. Crizotinib,a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases[J].Current Opinion in Investigational Drugs,2010,(12):1477-1490.
  • 10Soda M,Takada S,Takeuchi K. A mouse model for EML4-ALK-positive lung cancer[J].Proceedings of the National Academy of Sciences(USA),2008,(50):19893-19897.doi:10.1073/pnas.0805381105.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部